DSE : SILCOPHL
Silco Pharmaceuticals Limited — Key statistics
Pharmaceutical Preparations · Bangladesh
Last price 14.8 BDT (At close: Oct 29, 2026) · Market cap 1.54B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Technical report: trend, RSI, support and resistance, charts
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.54B |
| Enterprise Value | 1.51B |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 8, 2026 |
| Ex-Dividend Date | Nov 26, 2026 |
Shares
| Measure | Value |
|---|
| Current Share Class | 103.81M |
| Shares Outstanding | 103.81M |
| Shares Change (YoY) | +0.31% |
| Shares Change (QoQ) | +5.78% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Ratios
| Measure | Value |
|---|
| PE Ratio | 44.73 |
| Forward PE | n/a |
| PS Ratio | 3.76 |
| PB Ratio | 0.64 |
| P/TBV Ratio | 0.64 |
| P/FCF Ratio | 89.25 |
| P/OCF Ratio | 20.99 |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | 44.09 |
| EV / Sales | 3.69 |
| EV / EBITDA | 9.37 |
| EV / EBIT | 22.52 |
| EV / FCF | 87.66 |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 4.81 |
| Quick Ratio | 2.10 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.01 |
| Debt / FCF | 0.07 |
| Interest Coverage | 138.96 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | 1.42% |
| Return on Assets (ROA) | 1.48% |
| Return on Invested Capital (ROIC) | 1.43% |
| Return on Capital Employed (ROCE) | 2.61% |
| Weighted Average Cost of Capital (WACC) | 6.04% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 313 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 0.58 |
Taxes
| Measure | Value |
|---|
| Income Tax | 32.94M |
| Effective Tax Rate | 49.04% |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +8.82% |
| 50-Day Moving Average | 16.55 |
| 200-Day Moving Average | 16.66 |
| Relative Strength Index (RSI) | 42.04 |
| Average Volume (20 Days) | 248,911 |
Shortselling
| Measure | Value |
|---|
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Incomestatement
| Measure | Value |
|---|
| Revenue | 408.71M |
| Gross Profit | 139.31M |
| Operating Income | 67.00M |
| Pretax Income | 67.17M |
| Net Income | 34.23M |
| EBITDA | 156.36M |
| EBIT | 67.00M |
| Earnings Per Share (EPS) | 0.33 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 28.60M |
| Total Debt | 1.29M |
| Net Cash | 27.31M |
| Net Cash Per Share | 0.26 |
| Equity (Book Value) | 2.42B |
| Book Value Per Share | 23.27 |
| Working Capital | 839.32M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | 73.19M |
| Capital Expenditures | -55.98M |
| Depreciation & Amortization | 89.35M |
| Net Borrowing | -4.86M |
| Free Cash Flow | 17.21M |
| FCF Per Share | 0.17 |
Margins
| Measure | Value |
|---|
| Gross Margin | 34.09% |
| Operating Margin | 16.39% |
| Pretax Margin | 16.43% |
| Profit Margin | 8.37% |
| EBITDA Margin | 38.26% |
| EBIT Margin | 16.39% |
| FCF Margin | 4.21% |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | 0.11 |
| Dividend Yield | 0.74% |
| Dividend Growth (YoY) | -54.55% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 23.68% |
| FCF Payout Ratio | 30.15% |
| Buyback Yield | -0.31% |
| Shareholder Yield | 0.43% |
| Earnings Yield | 2.24% |
| FCF Yield | 1.12% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 20, 2019 |
| Split Type | Forward |
| Split Ratio | 1.1 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 3.69 |
| Piotroski F-Score | 6 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |